Cerebral Palsy

The association between proinflammatory cytokine polymorphisms and cerebral palsy in very preterm infants.

Kapitanović Vidak H1, Catela Ivković T, Jokić M, Spaventi R, Kapitanović S.

Abstract

Cerebral palsy (CP) is a nonprogressive motor disorder caused by white matter damage in the developing brain and is often accompanied with cognitive and sensory disabilities. The risk of CP is higher among infants born preterm than in more mature infants. Intrauterine infection/inflammation, activation of the cytokine network and elevated levels of proinflammatory cytokines in neonatal blood or in amniotic fluid to which the preterm infant is exposed, has been identified as the most common cause of preterm delivery, periventricular leukomalacia (PVL) and CP. The aim of our study was to evaluate the possible association of four TNFα promoter single nucleotide polymorphisms (SNPs) (-1031 T/C, -857 C/T, -308 G/A and -238 G/A), two IL1β SNPs (-511 C/T and +3954 C/T) and one IL6 (-174 C/G) polymorphism with susceptibility to CP in very preterm infants. Statistically significant association between TNFα -1031 T/C high expression genotypes (TC and CC) (OR, 2.339; p=0.016) as well as between TNFα -1031 C high expression allele (OR, 2.065; p=0.013) and risk of CP was observed. In addition, statistically significant association was found between TNFα TC, CC, GG, GG -1031/-857/-308/-238 genotypes combination (OR, 3.286; p=0.034) and risk of CP. Statistically significant association between IL1β TT, CC -511/+3954 genotypes combination and risk of CP (OR, 4.000; p=0.027) was also found. In CP patients with cystic PVL (cPVL) statistically significant association was found between TNFα -1031 T/C high expression genotypes (TC and CC) (OR, 2.361; p=0.038), IL1β -511 C/T high expression genotype TT (OR, 3.215; p=0.030) as well as IL1β -511 T high expression allele (OR, 1.956; p=0.019) and risk of CP. Statistically significant association was also found in patients with cPVL between TNFα TC, CC, GG, GG -1031/-857/-308/-238 genotypes combination (OR, 4.107; p=0.024), as well as IL1β TT, CC -511/+3954 genotypes combination (OR, 7.333; p=0.005) and risk of CP. Our results suggest the role of TNFα and IL1β polymorphisms which have previously been associated with higher circulating levels of these cytokines in genetic susceptibility to white matter damage and consequently CP in very preterm infants.

Copyright © 2012 Elsevier Ltd. All rights reserved.

PMID:
    22266275
    [PubMed - indexed for MEDLINE]

:: Courtesy NCBI (National Center for Biotechnology Information) Database and The NIH (National Institutes of Health) ::

http://www.ncbi.nlm.nih.gov/pubmed/22266275
http://www.hindawi.com/journals/ad/2014/237107/


The following product(s) are being used for the research of the above disease, illness or condition
Leptin Rat

Leptin Rat Recombinant

200µg - ($ 50)
1mg - ($ 130)
5mg - ($ 450)
Qty
NGB Human

Neuroglobin Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 4680)
Qty
SDF 1a Human

Stromal Cell-Derived Factor-1 Alpha Human Recombinant (CXCL12)

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 2700)
Qty
AGRP Human

Agouti–Related Protein Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 3600)
Qty
PTGDS Human

Beta Trace Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 4800)
Qty
CST3 Mouse

Cystatin-C Mouse Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 5200)
Qty
KLK1 Human

Kallikrein-1 Human Recombinant

20µg - ($ 50)
100µg - ($ 130)
1mg - ($ 1100)
Qty
CALM2 Human

Calmodulin-2 Human Recombinant

5µg - ($ 50)
25µg - ($ 130)
1mg - ($ 3600)
Qty
Fumarase Human

Fumarate Hydratase Human Recombinant

10µg - ($ 50)
50µg - ($ 130)
1mg - ($ 1800)
Qty
APP Antibody

Amyloid Beta A4 Protein, Mouse Anti Human

5µg - ($ 50)
20µg - ($ 130)
100µg - ($ 450)
Qty
NDE1 Human

nudE Nuclear Distribution Gene E Homolog 1 Human Recombinant

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 2700)
Qty
ASPA Human

Aspartoacylase Human Recombinant

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 3600)
Qty
APP Human

Amyloid beta (A4) Precursor Protein Human Recombinant

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 2700)
Qty
HAAO Human

3-Hydroxyanthranilate 3,4-Dioxygenase Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 5200)
Qty
CDNF Human

Cerebral Dopamine Neurotrophic Factor Human Recombinant

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 2700)
Qty
NDE1 Antibody

nudE Nuclear Distribution Gene E Homolog 1, Mouse Anti Human

5µg - ($ 50)
20µg - ($ 130)
100µg - ($ 450)
Qty
CDNF Mouse

Cerebral Dopamine Neurotrophic Factor Mouse Recombinant

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 2700)
Qty
CDNF Rat

Cerebral Dopamine Neurotrophic Factor Rat Recombinant

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 2700)
Qty
KLK1 Human, His

Kallikrein-1 Human Recombinant, His Tag

2µg - ($ 50)
10µg - ($ 130)
100µg - ($ 1200)
Qty
FGF14 Human

Fibroblast Growth Factor 14 Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 5200)
Qty
CD59 Human

CD59 Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
100µg - ($ 1200)
Qty

Note:

BioInfoMedical is a leading global provider of products and services used in gene, protein and cell research, drug discovery and development, biopharmaceutical manufacturing and transfer of new technologies.

BioInfoMedical specializes in satisfying customers demand for high quality cytokine products including E. coli, insect, and mammalian cell-derived recombinant proteins, monoclonal/polyclonal antibodies, and other cytokine-related reagents.

The specific products and services, offered by BioInfoMedical Biotechnology, range from cytokines and related molecules (such as interleukins, growth factors, chemokines), adhesion molecules, neurotrophic factors, proteases, receptors, developmental proteins, apoptosis and signal transduction-related molecules, and full Technology-License packages with a comprehensive course at ours/customers lab facility. Diagnostic tests are also available in broad spectrum of diseases - Staph, Strep, Malaria, Typhoid, Sexually Transmitted Diseases, autoimmune diseases, and diseases like Cerebral Palsy described on this page..

Please contact us with any questions or inquiries regarding our above stated goals. We will continue to update and improve on this website to meet the needs of You, our customers and to futher the larger, global need for disease research and ultimate cures.